Larson Financial Group LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Larson Financial Group LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 62.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 81 shares of the biopharmaceutical company’s stock after purchasing an additional 31 shares during the quarter. Larson Financial Group LLC’s holdings in Regeneron Pharmaceuticals were worth $58,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of REGN. CWA Asset Management Group LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $298,000. Sigma Planning Corp increased its holdings in shares of Regeneron Pharmaceuticals by 4.1% in the 3rd quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company’s stock worth $430,000 after buying an additional 16 shares during the last quarter. Nations Financial Group Inc. IA ADV increased its holdings in shares of Regeneron Pharmaceuticals by 3.5% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 1,082 shares of the biopharmaceutical company’s stock worth $1,137,000 after buying an additional 37 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $420,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $665,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $689.50 on Thursday. The company has a 50 day moving average price of $696.62 and a 200-day moving average price of $841.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20. The stock has a market capitalization of $75.38 billion, a PE ratio of 18.01, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the company earned $11.86 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.51%. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on REGN shares. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Sanford C. Bernstein reduced their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Bank of America restated an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.